RxDoctor Payments Data

Michael Gietzen, DO

Family Medicine · Pryor, OKNPI 1447273461

Payments from drug & device makers

$784in general payments, 2019–2025

Across 53 payments — averaging $14.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$245
  • Pfizer$110
  • Astellas Pharma US Inc$64
  • Abbott$55
  • Sanofi-aventis U.S. LLC$45
  • AstraZeneca$39
  • plus $226 from 10 others

What the payments were for

  • Food & beverage$784100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$784 in reported general payments places this provider in the 60th percentile of 1,730 family medicine providers in Oklahoma.

See all family medicine providers in Oklahoma

Medicare billing

Part B allowed, 2024
$10,026
Medicare patients
63
Services billed
411

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide124$123,727
OzempicSemaglutide77$84,007
EliquisApixaban64$66,961
Tresiba Flextouch U-200Insulin Degludec44$56,902
TrulicityDulaglutide54$56,741
JardianceEmpagliflozin44$43,666
Soliqua 100-33Insulin Glargine/Lixisenatide39$38,588
JanuviaSitagliptin Phosphate30$34,393
XareltoRivaroxaban28$32,714
Trelegy ElliptaFluticasone/Umeclidin/Vilanter44$28,769
FarxigaDapagliflozin Propanediol24$26,447
SymbicortBudesonide/Formoterol Fumarate30$11,931
BrilintaTicagrelor14$11,597
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog14$8,351
Atorvastatin Calcium481$7,706

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$19$180,468178 claims
Novo NordiskOzempic$245$84,00777 claims
PfizerEliquis$110$66,96164 claims
AstraZenecaFarxiga, Symbicort, Brilinta, Breztri Aerosphere$39$57,59380 claims
Boehringer IngelheimJardiance$31$43,66644 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$45$38,58839 claims
MerckJanuvia$15$34,39330 claims
Johnson & JohnsonXarelto$11$32,71428 claims
GSKTrelegy Ellipta$39$28,76944 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,730 family medicine providers in Oklahoma.

Other family medicine in Pryor

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →